FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Generic Drug User Fee Fix Passes Congress

[ Price : $8.95]

Congress passes the FDA User Fee Corrections Act of 2012, providing the agency with authority to collect and spend generic drug us...

FDA Clears Merit Medical Guide Wire

[ Price : $8.95]

FDA clears a Merit Medical Systems 510(k) to market its Merit Laureate hydrophilic guide wire after a February agency Warning Lett...

FDA Clears Teleflex ArrowFlexBlock Catheter

[ Price : $8.95]

FDA clears a Teleflex Inc. 510(k) application for the Arrow FlexBlock continuous peripheral nerve block catheter.

Novartis Positive Phase 3 Data for Heart Failure Candidate

[ Price : $8.95]

Novartis says Phase 3 study results show that investigational drug RLX030 (serelaxin) reduced all-cause mortality in patients with...

FDA Task Force Formed for Developing Antibacterial Drugs

[ Price : $8.95]

FDA forms an internal task force to help sponsors develop new antibacterial drugs.

Peregrine: Major Discrepancies in Phase 2 Lung Cancer Trial

[ Price : $8.95]

Peregrine Pharmaceuticals says it discovered major discrepancies with data coming from a Phase 2 trial of bavituximab in second-li...

FDA Guidance on Stability Data in ANDAs

[ Price : $8.95]

FDA says ICH guidances offered on stabilty data required for reviewing NDAs also applies to ANDAs.

Practical Advice on Responding to FDA-483 Observations

[ Price : $8.95]

An FDA compliance consultant says companies responding to FDA-483s on systemic corrections should provide a well-documented plan f...

FDA Seeks Participant Notification for Drug Development Meetings

[ Price : $8.95]

Federal Register Notice: FDA asks patient stakeholders to notify the agency of their intent to participate in meetings on drug dev...

Public Meeting on Patient-Focused Drug Development

[ Price : $8.95]

Federal Register Notice: FDA announces a public meeting 10/25 on the agencys patient-focused drug development initiative.